-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $27

Benzinga·11/11/2026 14:10:41
Listen to the news
Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $30 to $27.